

R E M A R K S

Applicant wishes to thank Examiners for their courtesy in granting the interview held on December 3, at which time claims 1 and 3 as above amended were discussed, as well as comments made herein. Note that in claim 1:

x<sub>1</sub>) The claimed method is limited to treatment of only FMF. No reference or combination of references suggests this.

x<sub>2</sub>) Administration is continued at the recited milligram level, and at said average daily basis level for as long as the FMF symptoms continue. No such administration, for only FMF, is suggested by the cited art.

x<sub>3</sub>) As to claims 3 and 4, based on claim 1,

- i) the LTRA is administered orally, and in tablet form,
- ii) about 10 milligrams of LTRA is administered on a daily basis,
- iii) and the LTRA consists of ZAFIRLUCAST tablets (claim 3) or SINGULAIR tablets (claim 4).


Serial No.10/826,901

No reference suggests i), ii) and iii) in combination with  $x_1$ ) and  $x_2$ ) above, in the totality of claim 1 subject matter, as now defined.

Reference is again made to the distinctions over the art, as were set forth in the previous amendment herein.

It is believed and urged that in view of the above and the interview, the now presented claims reasonably define over the cited and applied art, and should justifiably be formed allowable. A telephone call from Examiner to discuss any issue is invited.

Respectfully submitted,

  
William W. Haefliger  
Attorney for Applicant  
Registration No.17,120  
323 684-2707

WWH:hk  
Docket 12,616